{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:18:39Z","timestamp":1780679919985,"version":"3.54.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"6","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 AI113515"],"award-info":[{"award-number":["R21 AI113515"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Candida species are the second most frequent cause of fungal infections worldwide. Current knowledge of immunity to Candida has been gleaned almost exclusively from studies on Candida albicans, the most common disease-causing species. Knowledge of immunity to non-albicans Candida (NAC) species is still at an early stage due to the lack of tractable animal models with which to study these important pathogens. This is partly because many NAC species are not usually pathogenic in mouse models of candidiasis. In this study, we established an immunosuppressed mouse model of disseminated candidiasis by the two clinically important NAC species, C. glabrata and C. tropicalis. The inbred mouse strains, A\/J and BALB\/c, show distinct susceptibilities to disseminated Candida infection. A\/J mice, deficient for complement C5, are more susceptible to disseminated infection with both C. glabrata and C. tropicalis compared to BALB\/c mice, the latter having functional C5. Here we show that peptide-pulsed dendritic cell (DC) vaccination with a peptide derived from a C. tropicalis cell surface protein, significantly improved survival and reduced the fungal burdens of disseminated candidiasis in these immunocompromised mice. Importantly, this study is the first report of protective efficacy conferred by a peptide vaccine against medically important NAC species in immunosuppressed hosts. Establishing this experimental mouse model provides an important tool to further understand pathogenesis and host resistance in Candida infection. Significantly, our findings also demonstrate how this model can be used to evaluate new control strategies against candidiasis, such as vaccines.<\/jats:p>","DOI":"10.1093\/mmy\/myy122","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T20:11:34Z","timestamp":1542744694000},"page":"745-756","source":"Crossref","is-referenced-by-count":19,"title":["Effects of immune suppression in murine models of disseminated Candida glabrata and Candida tropicalis infection and utility of a synthetic peptide vaccine"],"prefix":"10.1093","volume":"57","author":[{"given":"Hong","family":"Xin","sequence":"first","affiliation":[{"name":"Louisiana State University Health Sciences Center, Microbiology and Immunology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,6]]},"reference":[{"key":"2019072120000339000_bib1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019072120000339000_bib2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/376906","article-title":"A prospective observational study of candidiemia: epidemiology, therapy, and influences on mortality in hosptilaized adult and pediatric patients","volume":"37","author":"Pappas","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2019072120000339000_bib3","first-page":"2173","article-title":"Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species","volume":"17","author":"Whaley","year":"2016","journal-title":"Front Microbiol"},{"key":"2019072120000339000_bib4","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s10096-003-0973-8","article-title":"Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis","volume":"22","author":"Colombo","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2019072120000339000_bib5","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated MIC","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2019072120000339000_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10096-013-2009-3","article-title":"Candida glabrata: a review of its features and resistance","volume":"33","author":"Rodrigues","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2019072120000339000_bib7","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.3201\/eid2011.140685","article-title":"Drug-resistant Candida glabrata infection in cancer patients","volume":"20","author":"Farmakiotis","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2019072120000339000_bib8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/jhin.2001.1151","article-title":"Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance","volume":"50","author":"Krcmery","year":"2002","journal-title":"J Hosp Infect"},{"key":"2019072120000339000_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/clinids\/20.1.115","article-title":"Importance of Candida species other than C. albicans as pathogens in oncology patients","volume":"20","author":"Wingard","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2019072120000339000_bib10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0002-9343(87)90949-1","article-title":"Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole","volume":"83","author":"Wingard","year":"1987","journal-title":"Am J Med"},{"key":"2019072120000339000_bib11","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1086\/323812","article-title":"Risk factors for Candida tropicalis fungemia in patients with cancer","volume":"33","author":"Kontoyiannis","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2019072120000339000_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3410\/M3-13","article-title":"Vaccines for invasive fungal infections","volume":"3","author":"Spellberg","year":"2011","journal-title":"F1000 Med Rep"},{"key":"2019072120000339000_bib13","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0264-410X(99)00089-4","article-title":"Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response","volume":"17","author":"Dockrell","year":"1999","journal-title":"Vaccine"},{"key":"2019072120000339000_bib14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1067\/mpd.2001.115972","article-title":"Immunization of HIV-infected children with varicella vaccine","volume":"139","author":"Levin","year":"2001","journal-title":"J Pediatr"},{"key":"2019072120000339000_bib15","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1086\/420740","article-title":"Hepatitis A and B vaccination practices for ambulatory patients infected with HIV","volume":"38","author":"Tedaldi","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2019072120000339000_bib16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-0609.2004.00216.x","article-title":"Immunogenicity of a two-dose regime of varicella vaccine in children with cancers","volume":"72","author":"Leung","year":"2004","journal-title":"Eur J Haematol"},{"key":"2019072120000339000_bib17","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMoa035060","article-title":"A trial of a 9-valent pneumococal conjugate vaccine in children with and those without HIV infection","volume":"340","author":"Klugman","year":"2003","journal-title":"N Engl J Med"},{"key":"2019072120000339000_bib18","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1128\/IAI.63.7.2714-2719.1995","article-title":"Antibody response that protects against disseminated candidiasis","volume":"63","author":"Han","year":"1995","journal-title":"Infect Immun"},{"key":"2019072120000339000_bib19","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1128\/IAI.68.3.1649-1654.2000","article-title":"Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody","volume":"68","author":"Han","year":"2000","journal-title":"Infect Immun"},{"key":"2019072120000339000_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0022-1759(02)00013-3","article-title":"A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells","volume":"262","author":"Son","year":"2002","journal-title":"J Immunol Meth"},{"key":"2019072120000339000_bib21","doi-asserted-by":"crossref","first-page":"13526","DOI":"10.1073\/pnas.0803195105","article-title":"Synthetic glycopeptide vaccines combining \u03b2-mannan and peptide epitopes induce protection against candidiasis","volume":"105","author":"Xin","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019072120000339000_bib22","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1128\/CVI.05215-11","article-title":"Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis","volume":"18","author":"Xin","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"2019072120000339000_bib23","first-page":"241","article-title":"Double chimeric peptide vaccine and monoclonal antibodies that protect against disseminated candidiasis","volume":"5","author":"Xin","year":"2014","journal-title":"J Vaccines Vaccin"},{"key":"2019072120000339000_bib24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1099\/jmm.0.045054-0","article-title":"Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options","volume":"62","author":"Sardi","year":"2013","journal-title":"J Med Microbiol"},{"key":"2019072120000339000_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/CMR.12.1.80","article-title":"Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans","volume":"12","author":"Fidel","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"2019072120000339000_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jof4010021","article-title":"Experimental in vivo models of candidiasis","volume":"4","author":"Segal","year":"2018","journal-title":"Journal of Fungi"},{"key":"2019072120000339000_bib27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijantimicag.2011.04.018","article-title":"Activity of an Intralipid formulation of nystatin in murine systemic candidiasis","volume":"38","author":"Semis","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2019072120000339000_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mycmed.2015.12.006","article-title":"Pathogenicity of Candida albicans isolates from bloodstream and mucosal candidiasis assessed in mice and Galleria mellonella","volume":"26","author":"Frenkel","year":"2016","journal-title":"J Mycol Med"},{"key":"2019072120000339000_bib29","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1128\/IAI.01244-09","article-title":"Candida glabrata persistence in mice does not depend on host immunosuppression and is unaffected by fungal amino acid auxotrophy","volume":"78","author":"Jacobsen","year":"2010","journal-title":"Infect Immun"},{"key":"2019072120000339000_bib30","doi-asserted-by":"crossref","first-page":"e25909","DOI":"10.1371\/journal.pone.0025909","article-title":"Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis","volume":"6","author":"Luo","year":"2011","journal-title":"PLoS One"},{"key":"2019072120000339000_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.vaccine.2015.11.035","article-title":"Active immunizations with peptide-DC vaccines and passive transfer with antibodies protect neutropenic mice against disseminated candidiasis","volume":"34","author":"Xin","year":"2016","journal-title":"Vaccine"},{"key":"2019072120000339000_bib32","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/sj.gene.6364254","article-title":"Genetic control of susceptibility to Candida albicans in susceptible A\/J and resistant C57BL\/6\u00a0J mice","volume":"6","author":"Tuite","year":"2005","journal-title":"Genes Immun"},{"key":"2019072120000339000_bib33","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/sj.gene.6364130","article-title":"Genetic analysis of innate immunity in resistance to Candida albicans","volume":"5","author":"Tuite","year":"2004","journal-title":"Genes Immun"},{"key":"2019072120000339000_bib34","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1128\/IAI.00233-09","article-title":"Complement C3 plays an essential role in the control of opportunistic fungal infections","volume":"77","author":"Tsoni","year":"2009","journal-title":"Infect Immun"},{"key":"2019072120000339000_bib35","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1128\/IAI.72.10.5868-5876.2004","article-title":"Dysregulated inflammatory resopnse to Candida albicans in a C5-deficient mouse strain","volume":"72","author":"Mullick","year":"2004","journal-title":"Infect Immun"},{"key":"2019072120000339000_bib36","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1128\/IAI.00159-06","article-title":"Cardiac failure in C5-deficient A\/J mice after Candida albicans infection","volume":"74","author":"Mullick","year":"2006","journal-title":"Infect Immun"},{"key":"2019072120000339000_bib37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.vetimm.2008.04.020","article-title":"Immune response to fungal infections","volume":"125","author":"Blanco","year":"2008","journal-title":"Vet Immunol Immunopathol"},{"key":"2019072120000339000_bib38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/21505594.2015.1004977","article-title":"Adaptive immune responses to Candida albicans infection","volume":"6","author":"Richardson","year":"2015","journal-title":"Virulence"},{"key":"2019072120000339000_bib39","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1128\/IAI.01001-07","article-title":"Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma","volume":"75","author":"Casadevall","year":"2007","journal-title":"Infect Immun"},{"key":"2019072120000339000_bib40","doi-asserted-by":"crossref","first-page":"e5392","DOI":"10.1371\/journal.pone.0005392","article-title":"Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence","volume":"4","author":"Torosantucci","year":"2009","journal-title":"PLoS One"},{"key":"2019072120000339000_bib41","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1128\/IAI.65.8.3399-3405.1997","article-title":"Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats","volume":"65","author":"De Bernardis","year":"1997","journal-title":"Infect Immun"},{"key":"2019072120000339000_bib42","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1016\/j.vaccine.2010.01.012","article-title":"Beta-glucan-CRM 197 conjugates as candidates antifungal vaccines","volume":"28","author":"Bromuro","year":"2010","journal-title":"Vaccine"},{"key":"2019072120000339000_bib43","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1084\/jem.20050749","article-title":"A novel glyco-conjugate vaccine against fungal pathogens","volume":"202","author":"Torosantucci","year":"2005","journal-title":"J Exp Med"},{"key":"2019072120000339000_bib44","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1128\/IAI.01840-06","article-title":"Fungicidal monoclonal antibody C7 binds to Candida albicans","volume":"75","author":"Brena","year":"2007","journal-title":"Infect Immun"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/57\/6\/745\/28937322\/myy122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T17:08:09Z","timestamp":1605460089000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/57\/6\/745\/5232120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,6]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,12,6]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myy122","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2018,12,6]]}}}